STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 102 filers reported holding STOKE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $686,869 | -61.8% | 174,332 | +3.0% | 0.00% | – |
| Q2 2023 | $1,799,531 | +7.5% | 169,288 | -15.7% | 0.00% | – |
| Q1 2023 | $1,673,472 | -70.4% | 200,897 | -67.2% | 0.00% | -100.0% |
| Q4 2022 | $5,649,259 | -65.2% | 612,054 | -51.6% | 0.00% | -66.7% |
| Q3 2022 | $16,221,000 | -2.4% | 1,263,399 | +0.4% | 0.00% | 0.0% |
| Q2 2022 | $16,619,000 | -33.6% | 1,258,113 | +5.9% | 0.00% | -25.0% |
| Q1 2022 | $25,011,000 | +1264.5% | 1,188,115 | +2070.1% | 0.00% | – |
| Q3 2020 | $1,833,000 | +398.1% | 54,750 | +254.4% | 0.00% | – |
| Q2 2020 | $368,000 | -87.7% | 15,448 | -88.2% | 0.00% | -100.0% |
| Q1 2020 | $3,004,000 | -43.3% | 131,180 | -29.9% | 0.00% | 0.0% |
| Q4 2019 | $5,302,000 | +70.2% | 187,248 | +29.2% | 0.00% | 0.0% |
| Q3 2019 | $3,115,000 | -73.7% | 144,923 | -64.3% | 0.00% | -66.7% |
| Q2 2019 | $11,858,000 | – | 406,471 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $9,991,000 | 2.07% |
| RTW INVESTMENTS, LP | 3,644,248 | $122,665,000 | 1.85% |
| Cormorant Asset Management, LP | 1,278,276 | $43,027,000 | 1.46% |
| Redmile Group, LLC | 2,458,558 | $82,755,000 | 1.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 233,135 | $7,847,000 | 0.53% |
| Birchview Capital, LP | 15,000 | $505,000 | 0.30% |
| Perceptive Advisors | 1,343,956 | $45,238,000 | 0.29% |
| GILDER GAGNON HOWE & CO LLC | 1,245,956 | $41,939,000 | 0.21% |
| Artal Group S.A. | 250,000 | $8,415,000 | 0.17% |
| Casdin Capital, LLC | 120,000 | $4,039,000 | 0.10% |